生物医药系列产品
数据
资源
版本对比
免费注册
预约演示
免费注册
Neurocrine
Biosciences Presents Data on
Benztropine
Use Among People Treated with
Antipsychotics
at the 2022 American Psychiatric Nurses Association (APNA) Annual Conference
2022-10-19
·
BioSpace
SAN DIEGO, Oct. 19, 2022 /PRNewswire/ --
Neurocrine Biosciences, Inc.
(Nasdaq: NBIX) today announced data on the real-world comorbidities, polypharmacy, and treatment patterns of patients on newly prescribed
benztropine
who were also being treated with antipsychotic medications. This research will be presented at the 2022 American Psychiatric Nurses Association (APNA) Annual Conference being held October 19–22 both virtually and in Long Beach, CA. The new findings are from a retrospective 24-month observational study of claims between January 1, 2017, and March 30, 2020 (Poster #152; Characteristics, Polypharmacy, and Medication Adherence Among Patients Prescribed
Benztropine
with a History of Antipsychotic Use).
Benztropine
is an
anticholinergic
medication approved as an adjunct for treatment of all forms of
parkinsonism
, including
drug-induced parkinsonism
that causes movement problems similar to those seen in
Parkinson's disease
, such as
tremors
, slow movement, and stiffness.
Benztropine
can also be used to control other
antipsychotic-induced movement disorders
, except for
tardive dyskinesia (TD)
. The analysis found that the patient population, who received at least one new
benztropine
prescription during the study, often had multiple comorbidities, substantial polypharmacy, and mild, moderate, or severe anticholinergic burden associated with the medications patients were taking prior to initiation of
benztropine
. After starting
benztropine
, 38 percent of these patients were on this medication for longer than six months, exceeding recommendations for acute use. These results indicate that regular evaluation of
anticholinergic
use is clinically warranted, especially in patients who are taking multiple medications with
anticholinergic
properties and have an increased risk of adverse anticholinergic effects. "The use of
benztropine
may be appropriate for acute treatment of some
antipsychotic-induced movement disorders
, but not for
tardive dyskinesia
," said Eiry W. Roberts, MD, Chief Medical Officer at Neurocrine Biosciences. "In fact, antiparkinson agents like
benztropine
do not alleviate the symptoms of
TD
and may even aggravate them. These data help characterize the need for increased education regarding appropriate use of anticholinergic medications." Additional Presentations Include: Global Improvements and Psychiatric Stability in Adults with
Tardive Dyskinesia
: Post Hoc Analyses of Two Long-Term
Valbenazine
Studies (Poster #155) Long-Term
Valbenazine
Is Effective for
Tardive Dyskinesia
in Elderly Patients (≥65 Years) (Poster #164) The full abstracts being presented by Neurocrine Biosciences at the 2022 APNA Annual Conference can be accessed by registering for the meeting here. About
Tardive Dyskinesia (TD)
Tardive dyskinesia (TD)
is a
movement disorder
that is characterized by uncontrollable, abnormal, and repetitive movements of the face, torso, and/or other body parts, which may be disruptive and negatively impact patients. The condition is associated with taking certain kinds of mental health medicines (like
antipsychotics
) that help control
dopamine receptors
in the brain. Taking
antipsychotics
commonly prescribed to treat
mental illnesses
such as
depression
,
bipolar disorder
,
schizophrenia
, and
schizoaffective disorder
, and certain medications to treat
upset stomach
,
nausea
and
vomiting
are associated with
TD
. In patients with
TD
, these treatments are thought to result in irregular dopamine signaling in a region of the brain that controls movement. The symptoms of
TD
can be severe and are often persistent and irreversible. TD is estimated to affect approximately 600,000 people in the U.S. About
INGREZZA
® (
valbenazine
) Capsules
INGREZZA
, a selective
vesicular monoamine transporter 2 (VMAT2) inhibitor
, is an FDA-approved product indicated for the treatment of adults with
tardive dyskinesia
, a condition associated with uncontrollable, abnormal, and repetitive movements of the face, torso, and/or other body parts.
INGREZZA
is thought to work by reducing the amount of dopamine released in a region of the brain that controls movement and motor function, helping to regulate nerve signaling in adults with
tardive dyskinesia
.
VMAT2
is a protein in the brain that packages neurotransmitters, such as dopamine, for transport and release in presynaptic neurons.
INGREZZA
, developed by
Neurocrine Biosciences
, is novel in that it selectively inhibits
VMAT2
with no appreciable binding affinity for
VMAT1
, dopaminergic (including D2), serotonergic, adrenergic, histaminergic, or muscarinic receptors. Additionally,
INGREZZA
can be taken for the treatment of
tardive dyskinesia
as one capsule, once-daily, together with most psychiatric medications such as
antipsychotics
or
antidepressants
. Important Information Approved Use
INGREZZA
® (
valbenazine
) capsules is a prescription medicine used to treat adults with movements in the face, tongue, or other body parts that cannot be controlled (
tardive dyskinesia
). It is not known if
INGREZZA
is safe and effective in children. IMPORTANT SAFETY INFORMATION Do not take
INGREZZA
if you: are allergic to
valbenazine
, or any of the ingredients in
INGREZZA
.
INGREZZA
may cause serious side effects, including:
Sleepiness
(
somnolence
). Do not drive, operate heavy machinery, or do other dangerous activities until you know how
INGREZZA
affects you. Heart rhythm problems (QT prolongation).
INGREZZA
may cause a heart problem known as
QT prolongation
. Symptoms of
QT prolongation
may include: fast, slow, or irregular heartbeat
shortness of breath dizziness
or
fainting
Tell your healthcare provider right away if you have a change in your heartbeat (a fast or irregular heartbeat), or if you faint. Abnormal movements (Parkinson-like). Symptoms include: shaking,
body stiffness
, trouble moving or walking, or keeping your balance. Before taking
INGREZZA
, tell your healthcare provider about all of your medical conditions including if you: have liver or heart problems, are pregnant or plan to become pregnant, or are breastfeeding or plan to breastfeed. Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. The most common side effect of
INGREZZA
is
sleepiness
(
somnolence
). Other side effects include changes in balance (balance problems,
dizziness
) or an increased risk of falls,
headache
, feelings of
restlessness
,
dry mouth
,
constipation
, and blurred vision. These are not all of the possible side effects of
INGREZZA
. Call your doctor for medical advice about side effects. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit MedWatch at or call 1-800-FDA-1088. Please see accompanying
INGREZZA
full Product Information. About
Neurocrine Biosciences
Neurocrine Biosciences
is a neuroscience-focused, biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs, but few options. We are dedicated to discovering and developing life-changing treatments for patients with under-addressed
neurological, neuroendocrine, and neuropsychiatric disorders
. The company's diverse portfolio includes FDA-approved treatments for
tardive dyskinesia
,
Parkinson's disease
,
endometriosis
,* and
uterine fibroids
,* as well as over a dozen mid- to late-stage clinical programs in multiple therapeutic areas. For three decades, we have applied our unique insight into neuroscience and the interconnections between brain and body systems to treat complex conditions. We relentlessly pursue medicines to ease the burden of debilitating diseases and disorders because you deserve brave science. For more information, visit neurocrine.com, and follow the company on LinkedIn, Twitter, and Facebook. (*In collaboration with
AbbVie
).
Neurocrine
, the
Neurocrine
logo, and
INGREZZA
are registered trademarks of
Neurocrine Biosciences, Inc.
Forward-Looking Statements In addition to historical facts, this press release contains forward-looking statements that involve a number of risks and uncertainties. These statements include, but are not limited to, statements regarding the potential benefits to be derived from
INGREZZA
and the value
INGREZZA
may bring to patients. Among the factors that could cause actual results to differ materially from those indicated in the forward-looking statements are: risks and uncertainties associated with the commercialization of
INGREZZA
; risks that clinical trial activities may not be predictive of real-world results or of results in subsequent clinical trials; risks that
INGREZZA
may be precluded from commercialization by the proprietary rights of third parties, or have unintended side effects or adverse reactions; risks and uncertainties relating to competitive products and technological changes that may limit demand for
INGREZZA
; risks associated with our dependence on third parties for development and manufacturing activities related to INGREZZA and our product candidates, and our ability to manage these third parties; risks that the FDA or other regulatory authorities may make adverse decisions regarding our products or product candidates; risks that our products, and/or our product candidates may be precluded from commercialization by the proprietary or regulatory rights of third parties, or have unintended side effects, adverse reactions or incidents of misuse; risks associated with potential generic entrants for our products; risks and uncertainties associated with the scale and duration of the COVID-19 pandemic and resulting global, national, and local economic and financial disruptions; and other risks described in the Company's periodic reports filed with the Securities and Exchange Commission, including without limitation the Company's quarterly report on Form 10-Q for the quarter ended June 30, 2022.
Neurocrine Biosciences
disclaims any obligation to update the statements contained in this press release after the date hereof. ©2022
Neurocrine Biosciences, Inc.
All Rights Reserved. Company Codes: NASDAQ-NMS:NBIX
更多内容,
请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点,如有版权侵扰或错误之处,请及时联系我们,我们会在24小时内配合处理。
机构
Neurocrine Biosciences, Inc.
AbbVie, Inc.
适应症
胃病
分裂情感性障碍
平滑肌瘤
[+25]
靶点
DRDs
VMAT2
VMAT1
药物
氢溴酸苯甲托品
F-97013-GD
WL-8713
[+2]
标准版
¥
16800
元/账号/年
新药情报库 | 省钱又好用!
立即使用
来和芽仔聊天吧
热门报告
特应性皮炎深度解析:药物开发、专利分析与风险评估
智慧芽生物医药
2024年7月全球首批及特殊审评药物报告
智慧芽生物医药
GPRC5D靶点专利调研报告
智慧芽生物医药
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台,助您全方位提升您的研发与决策效率。
开始免费试用
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台,以API或者数据包形式对外开放,助您更加充分利用智慧芽新药情报信息。
试用数据服务